143 related articles for article (PubMed ID: 23324244)
1. [Mechanisms of resistance to crizotinib in patients with transforming EML4-ALK fusion gene].
Zhang HJ; Zhang XT; Zhang L
Zhonghua Bing Li Xue Za Zhi; 2012 Dec; 41(12):862-4. PubMed ID: 23324244
[No Abstract] [Full Text] [Related]
2. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells.
Tanimoto A; Yamada T; Nanjo S; Takeuchi S; Ebi H; Kita K; Matsumoto K; Yano S
Oncotarget; 2014 Jul; 5(13):4920-8. PubMed ID: 24952482
[TBL] [Abstract][Full Text] [Related]
3. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
[TBL] [Abstract][Full Text] [Related]
4. [Study of EML4-ALK fusion gene as a biomarker in non-small cell lung cancer].
Wang L; Wang YH; Liu CY; Han M; Zhang SP; Lai RS
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):788-90. PubMed ID: 22336170
[No Abstract] [Full Text] [Related]
5. Crizotinib in the management of advanced-stage non-small-cell lung cancer.
Loong HH; Mok K; Leung LK; Mok TS
Future Oncol; 2015; 11(5):735-45. PubMed ID: 25757678
[TBL] [Abstract][Full Text] [Related]
6. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
7. [Clinical research of crizotinib in advanced non-small cell lung cancer].
Zhu H; Xu X; Wang L
Zhongguo Fei Ai Za Zhi; 2013 Jun; 16(6):321-4. PubMed ID: 23769348
[TBL] [Abstract][Full Text] [Related]
8. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.
Heuckmann JM; Balke-Want H; Malchers F; Peifer M; Sos ML; Koker M; Meder L; Lovly CM; Heukamp LC; Pao W; Küppers R; Thomas RK
Clin Cancer Res; 2012 Sep; 18(17):4682-90. PubMed ID: 22912387
[TBL] [Abstract][Full Text] [Related]
9. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
Nilsson RJ; Karachaliou N; Berenguer J; Gimenez-Capitan A; Schellen P; Teixido C; Tannous J; Kuiper JL; Drees E; Grabowska M; van Keulen M; Heideman DA; Thunnissen E; Dingemans AM; Viteri S; Tannous BA; Drozdowskyj A; Rosell R; Smit EF; Wurdinger T
Oncotarget; 2016 Jan; 7(1):1066-75. PubMed ID: 26544515
[TBL] [Abstract][Full Text] [Related]
10. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation.
Costa DB; Kobayashi S
J Thorac Oncol; 2012 Mar; 7(3):623-5. PubMed ID: 22334013
[No Abstract] [Full Text] [Related]
11. Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation?
Chun SG; Choe KS; Iyengar P; Yordy JS; Timmerman RD
Cancer Biol Ther; 2012 Dec; 13(14):1376-83. PubMed ID: 22986231
[TBL] [Abstract][Full Text] [Related]
12. Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangement.
Maillet D; Martel-Lafay I; Arpin D; Pérol M
J Thorac Oncol; 2013 Apr; 8(4):e30-1. PubMed ID: 23486270
[No Abstract] [Full Text] [Related]
13. Favorable response to crizotinib in three patients with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion-type oncogene-positive non-small cell lung cancer.
Kijima T; Takeuchi K; Tetsumoto S; Shimada K; Takahashi R; Hirata H; Nagatomo I; Hoshino S; Takeda Y; Kida H; Goya S; Tachibana I; Kawase I
Cancer Sci; 2011 Aug; 102(8):1602-4. PubMed ID: 21767331
[TBL] [Abstract][Full Text] [Related]
14. Resistance: Crizotinib makes a comeback.
Shipman L
Nat Rev Cancer; 2016 Feb; 16(2):69. PubMed ID: 26797648
[No Abstract] [Full Text] [Related]
15. Crizotinib Resensitization by Compound Mutation.
Bordi P; Del Re M; Tiseo M
N Engl J Med; 2016 May; 374(18):1790. PubMed ID: 27144863
[No Abstract] [Full Text] [Related]
16. Crizotinib Resensitization by Compound Mutation.
Shaw AT; Engelman JA
N Engl J Med; 2016 May; 374(18):1790-1. PubMed ID: 27144862
[No Abstract] [Full Text] [Related]
17. Crizotinib-induced acute interstitial lung disease in a patient with EML4-ALK positive non-small cell lung cancer and chronic interstitial pneumonia.
Watanabe N; Nakahara Y; Taniguchi H; Kimura T; Kondoh Y; Kataoka K; Sakamoto K
Acta Oncol; 2014 Jan; 53(1):158-60. PubMed ID: 23750540
[No Abstract] [Full Text] [Related]
18. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
19. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
[TBL] [Abstract][Full Text] [Related]
20. Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?
Crystal AS; Shaw AT
Clin Cancer Res; 2012 Sep; 18(17):4479-81. PubMed ID: 22912388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]